References
- Barrett-Lee PJ, NBailey NP, O’Brien ME, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93–7
- Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematological Oncology 2001;19:19–30
- Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multicentre patient survey. Cancer Fatigue Forum. Annals of Oncology 2000; 11:971–5
- Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–74
- Fallowfield L, et al. Multivariate regression analyses of data from a randomised, double blind, placebo controlled study to confirm quality of life benefit of epoetin alfa in patients receiving nonplatinum chemotherapy. Br J Cancer 2002; 87: 1341–53 [See also S9–11 of this issue]
- Cella D, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anaemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21(2): 366–73 [See also S12–15 of this issue]
- Jones, et al. Cancer 2004/5 in press [See also S16-18 of this issue]
- Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQoL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39; 335–45 [See also S3-5 of this issue]
- Fairclough DL, Gagnon DD, Zagari MJ, et al. Evaluation of quality of life in a clinical trial with non-random dropout: the effect of epoetin alfa in anaemic cancer patients. Qual Life Res. 2003; 12(8): 1013–27 [See also S6-8 of this issue]
- Littlewood TJ, Zagari M, Pallister C, et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anaemic cancer patients. The Oncologist 2003; 8(1): 99–107 [See also S19–21 of this issue]